Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01034865
Risk Factors and Molecular Genomics for Hepatocellular Carcinoma in U.S. Patients With Chronic Liver Disease: A Case Control Study
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Professor of Medicine (Gastroenterology and Hepatology) at the Palo Alto Veterans Affairs Health Care System
Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology, Hepatology and Nutrition)
- For both experimental subjects and controls:
1. Patients between older than 18 years of age of all ethnic backgrounds and
2. Patients with chronic liver disease
- For Experimental Subjects Only:
1. Patients with HCC with a hepatic mass larger or equal to 5cm
2. Patients with HCC with a hepatic mass lesion confirmed by fine needle aspirate
(FNA) or by pathology in the cases of surgical resection
3. Patients with HCC with a hepatic mass lesion with characteristic CT or MRI or
- For Controls Only:
Patients with chronic liver disease without evidence of HCC confirmed by either :
1. A normal AFP level
2. a negative imaging study (ultrasound, CT, or MR imaging).
3. Negative liver cancer on explants.
1. Patients who declined to participate in the study
2. Patients with a history of HIV infection
3. Patients with concurrent advanced malignancy of non-hepatic origin.
4. Patients with significant use of androgenic steroid.
5. Patients with exposure to vinyl chloride.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305